Fate raises $57M; Biogen vet named CSO at Scholar Rock

Jeffrey Flier

Jeffrey Flier

San Diego-based Fate Therapeutics $FATE has raised $57 million through a private placement of shares. Redmile bought 2.8 million preferred shares at $13.30 each, which convert into 5 common shares. The rest of the group acquired 7.2 million common shares at $2.66 each. Fate says it plans to use most of the money on its pipeline work.

Jeffrey Flier, the former dean of faculty of medicine at Harvard, is joining Scholar Rock’s board and scientific advisory group. Biogen vet Alan J. Buckler, meanwhile, is stepping into the Cambridge, MA-based group as CSO.

The FDA has OK’d Allergan’s XEN Glaucoma Treatment System, which consists of the XEN45 Gel Stent and injector.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Chief Medical Officer
Skyhawk Therapeutics Waltham, MA
Chief of Staff, North America
Ipsen Biopharmaceuticals Cambridge, MA
Senior Director, NA Digital Customer Interaction
Ipsen Biopharmaceuticals Cambridge, MA
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Quality Control (QC) Associate
Molecular Templates Austin, TX

Visit Endpoints Careers ->